Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Sulfur hexafluoride · Lumason

Other · developed by Bracco

Approved FDA, Oct 2014
1 Registered trials

What is Sulfur hexafluoride?

Sulfur hexafluoride lipid microspheres are an ultrasound contrast agent (Lumason) given intravenously to enhance imaging during sonography.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as
Lumason
Drug type
Other
Therapy area
Renal & urology
Developer
Bracco
In trials of
LNTH
FDA status
Approved as Lumason (October 10, 2014), NDA203684
UNII
WS7LR3I1D6

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT03907657 Phase 2 Von-Hippel Lindau Completed LNTH

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Kidney Disease, ChronicVon-Hippel Lindau

Sources

Updated Oct 18, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.